Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
CESTO 2 is a 318 participants, 3-arm, multicentric, randomized, double-blind,
placebo-controlled Phase II clinical trial.
The main objectives are to select the most efficient dose and to assess long-term efficacy of
NFL-101 compared to placebo, for abrupt cessation and for reduction before cessation.